FATE Logo

Fate Therapeutics, Inc. (FATE) 

NASDAQ
Market Cap
$247.72M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
202 of 775
Rank in Industry
116 of 432

Largest Insider Buys in Sector

FATE Stock Price History Chart

FATE Stock Performance

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid …

Insider Activity of Fate Therapeutics, Inc.

Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $166,024 and sold $245,937 worth of Fate Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $27.68M and sold $22.12M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Redmile Group, LLC () — $1.83M.

The last purchase of 44,630 shares for transaction amount of $166,024 was made by Redmile Group, LLC () on 2023‑12‑26.

List of Insider Buy and Sell Transactions, Fate Therapeutics, Inc.

2024-08-06Saledirector
633
0.0005%
$4.23$2,678-21.45%
2024-03-04SaleChief Financial Officer
2,447
0.0027%
$7.77$19,013-45.41%
2024-01-29SaleChief Financial Officer
1,849
0.0017%
$5.00$9,245-29.61%
2024-01-09SalePresident and CEO
14,391
0.0145%
$4.37$62,889-7.48%
2024-01-09SaleChief R&D Officer
11,271
0.0114%
$4.38$49,367-7.48%
2024-01-09SaleGeneral Counsel and Secretary
10,874
0.0109%
$4.37$47,519-7.48%
2024-01-09SaleChief Financial Officer
7,028
0.0071%
$4.37$30,712-7.48%
2024-01-02SaleChief Financial Officer
5,182
0.0052%
$3.66$18,966+10.91%
2023-12-26Purchase
44,630
0.0455%
$3.72$166,024+7.90%
2023-12-18SaleChief Financial Officer
1,585
0.0018%
$3.50$5,548+26.38%
2023-11-09SaleGeneral Counsel and Secretary
24,363
0.0278%
$2.40$58,471+81.31%
2023-08-18SaleChief Financial Officer
4,718
0.0048%
$2.80$13,210+35.25%
2023-08-04Saledirector
632
0.0006%
$3.71$2,345-0.80%
2023-07-05SaleChief Financial Officer
5,182
0.0053%
$4.83$25,029-22.74%
2023-07-05SaleChief Commercial Officer
3,854
0.0039%
$4.87$18,769-22.74%
2023-06-14Saledirector
3,460
0.0036%
$5.58$19,307-28.91%
2023-04-21Purchase
256,639
0.26%
$6.18$1.59M-27.09%
2023-04-20Purchase
20,000
0.0204%
$5.99$119,800-24.29%
2023-04-18SaleChief Medical Officer
2,532
0.0027%
$6.57$16,648-26.97%
2023-04-14Sale
302,339
0.2996%
$5.84$1.77M-24.54%

Insider Historical Profitability

1.32%
Redmile Group, LLC
13180388
11.5725%
$2.1881+12.66%
NELSEN ROBERT
2473188
2.1715%
$2.1810<0.0001%
ARCH VENTURE FUND VI LP10 percent owner
2473188
2.1715%
$2.1810<0.0001%
VENROCK ASSOCIATES V LP10 percent owner
2473187
2.1715%
$2.1810<0.0001%
Polaris Venture Management Co. V, L.L.C.10 percent owner
2473186
2.1715%
$2.1810<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Redmile Group$96.66M11.5713.17M0%+$00.99
The Vanguard Group$72.75M8.719.91M+6.65%+$4.53M<0.01
BlackRock$66.79M7.999.1M-18.84%-$15.51M<0.01
Boxer Capital, LLC$60.3M7.228.22M+1,543.18%+$56.63M1.24
State Street$58.99M7.068.04M+331.63%+$45.32M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.